

Amendments to the Drawings

Applicants enclose a replacement drawing of FIG. 2 that includes sequence identifiers in accordance with 37 C.F.R. §1.821. In addition, the first and second boxed regions in the replacement drawing have been amended and typographical errors in the PKC β II and CAPRI sequences have been corrected.

Applicants have identified the replacement drawings as a “Replacement Sheet.”

Remarks

Claims 1-59 have been cancelled without prejudice to their subsequent reintroduction into this application or their introduction into a related application. New claims 60-80 have been added. Upon entry of this paper, claims 60-80 will be pending and under consideration.

Support for new claims 60-80 appear throughout the specification and claims as filed. Support for new claim 60 appears, for example, in the second paragraph on page 8, in the third full paragraph on page 9, in the fourth full paragraph on page 15, in the second full paragraph on page 16, and in claims 3, 17, 18, and 20 of the application as originally filed. Support for new claim 61 appears, for example, in the last paragraph on page 14 and in claim 9 of the application as originally filed. Support for new claims 62 and 63 appears, for example, in the second full paragraph on page 14 and in claims 10 and 11 of the application as originally filed. Support for new claim 64 and 65 appears, for example, in the first full paragraph on page 9, in the first and second paragraphs on page 15, and in claims 14 and 15 of the application as originally filed. Support for new claims 66 and 67 appears, for example, in the first full paragraph on page 27 and in claims 12 and 16 of the application as originally filed. Support for new claims 68-71 appears, for example, in the third and fourth full paragraphs on page 16 and in claims 21-24 of the application as originally filed.

Support for new claims 72-76 appears, for example, in the paragraph bridging pages 17 and 18, in the second full paragraph on page 18, in the third and fourth paragraphs on page 21, and in claims 31, 34-35, and 44-48 of the application as originally filed. Support for new claim 77 appears, for example, in the third and fourth paragraphs on page 12 and in claim 50 of the application as originally filed. Support for new claim 78-79 appears, for example, in the second paragraph on page 25 and in claim 51 of the application as originally filed. Support for new claim 80 appears, for example, in the fourth full paragraph on page 26 and in claim 54 of the application as originally filed.


Applicant has amended paragraphs in the specification and has amended the replacement drawing of FIG. 2 to include correct sequence identifiers in accordance with 37 C.F.R. §1.821.

In addition, the first and second boxed regions in the replacement drawing of FIG. 2 have been amended to include the correct portions of the sequences, as described and supported in the paragraph bridging pages 6 and 7, in the third full paragraph on page 36, in the paragraph bridging pages 38 and 39, in the last paragraph on page 39, and in SEQ ID NO: 3 and SEQ ID NO: 5 on page 49 of the application as originally filed. The replacement drawing of FIG. 2 has also been amended to correct a typographical error in the PKC β II sequence following FQL and to correct a typographical error in the CAPRI sequence following FEL. Both sequences were known in the art prior to the earliest priority date of the application, for example, as described in Figure 1B of Lockyer *et al.* (2001) CURRENT BIOLOGY 11: 981-986 (included as C13 on the Form PTO-1449 included herewith).

In addition, Applicant provides a Sequence Listing in paper and computer-readable forms. The content of the paper and the computer-readable copy are the same. Applicant submits that support for the Sequence Listing is found throughout the application, for example, at pages 48-49 and in FIG. 2 of the application as originally filed.

Applicant believes that the aforementioned new claims, amendments to the specification, amendments to FIG. 2, and introduction of a Sequence Listing introduce no new matter. The Office is invited to contact the undersigned attorney to discuss any matters relating to the application. Early favorable action is respectfully solicited.

Respectfully submitted,



Randall D. Morin
Attorney for Applicant
Goodwin Procter LLP
Exchange Place
Boston, Massachusetts 02109
Customer No. 051414

Date: July 19, 2006
Reg. No. 58,312

Tel. No.: (617) 570-1657
Fax No.: (617) 523-1231